Human papillomavirus vaccines and adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 5, 2005, Pages 476-482

  Kahn, Jessica A ^a,b   Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Adolescent; Human papillomavirus; Vaccines

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER SCREENING; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; PAIN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

EID: 25444496225     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000179505.14623.ef     Document Type: Review

References (51)

1. Kahn JA, Hillard PA. Human papillomavirus and cervical cytology in adolescents. Adolesc Med Clin 2004; 15:301-321, ix. A comprehensive review of HPV and cervical cytology in adolescents.
2. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
3. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363:1488-1489.
4. Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458-467.
5. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101:270-280.
6. Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998; 27:796-806.
7. Tjiong MY, Out TA, Ter Schegget J, et al. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical carcinoma in the lower female genital tract: a review. Int J Gynecol Cancer 2001; 11:9-17.
8. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89:213-228.
9. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-192. The investigators used repeated self-collected vaginal specimens and clinician-collected cervical specimens to characterize the natural history of HPV infection in adolescent girls, and found that the cumulative prevalence rate of HPV infection over a 2-year period was extremely high.
10. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
11. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324:17-27. A comprehensive review of HPV taxonomy that provides an explanation of papillomavirus types, subtypes and variants.
12. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-284.
13. Lowy DR, Howley PM. Papillomaviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. Vol. 2, 4th ed. Philadelphia, PA: Lippincott; 2001. pp. 2231-2264.
14. Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645-652.
15. Bergler WF, Gotte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000; 257:263-269.
16. von Krogh G, Lacey CJ, Gross G, et al. European guideline for the management of anogenital warts. Int J STD AIDS 2001; 12 (Suppl 3):40-47.
17. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003; 31:111-116.
18. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2:343-347. An excellent review of the current status of HPV vaccines and issues that are critical to effective vaccine implementation.
19. Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2005; 10:5-19. An outstanding review of HPV vaccines in development and goals of ongoing research.
20. Gravitt PE, Shah KV. A virus-based vaccine may prevent cervical cancer. Curr Infect Dis Rep 2005; 7:125-131. A concise update on HPV vaccines and their public health implications.
21. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67:315-322.
22. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67:6929-6936.
23. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004; 22:2943-2952. One of the first studies to show that prophylactic vaccines are well tolerated and immunogenic in humans.
24. Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22:3004-3007. As above, one of the first studies to demonstrate that prophylactic vaccines are well tolerated and immunogenic.
25. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
26. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765. This manuscript is the first to describe the efficacy, tolerance and immunogenicity of a bivalent HPV-16/18 vaccine in young women. The vaccine was well tolerated and efficacious in preventing persistent HPV-16/18 infection and associated cytological abnormalities.
27. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L2 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; published online 7 April 2005: DOI 10.1016/S1470-2045(05)70101-7. This is the first published study to describe the tolerance and efficacy of a quadrivalent HPV-6/11/16/18 vaccine in young women. The vaccine was well tolerated and led to a 90% decrease in incidence of persistent infection or disease with HPV 6, 11, 16 or 18.
28. Reinis M. Technology evaluation: HPV vaccine (quadrivalent). Aventis Pasteur MSD/CSL Curr Opin Mol Ther 2004; 6:206-211.
29. Simon P, Buxant F, Hallez S, et al. Cervical response to vaccination against HPV16 E7 in case of severe dysplasia. Eur J Obstet Gynecol Reprod Biol 2003; 109:219-223.
30. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53:642-650. In this multicenter phase I/II trial, injection with a fusion protein vaccine generated systemic immune responses in most of the women with CIN 1 and CIN 3 who participated in the study.
31. Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN1, CIN2, and CIN3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15:421-431. In this promising phase I/II clinical protocol, direct inoculation of CIN lesions with a vaccinia virus vector carrying HPV antigens (MVA E2) led to eradication of some lesions, stimulated production of antibodies and cytotoxic T-cells, and led to reduction of HPV viral load in HPV-infected patients.
32. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63:6032-6041.
33. Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004; 22:2722-2729. In this study, the investigators use a strategy of heterologous prime-boost vaccination in women with vulvar intraepithelial neoplasia. Most participants demonstrated HPV 16-specific cytotoxic T-cell or antibody responses after vaccination and some demonstrated reduction in lesion size.
34. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004; 10:2954-2961.
35. Neefe JR, Chu NR, Mizzen L. CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer. Dev Biol (Basel) 2004; 116:193-200; discussion 229-236.
36. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999; 179:612-618.
37. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 2003; 21:787-790.
38. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129:521-530.
39. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63-73.
40. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111:278-285. In this study, investigators demonstrate that there are geographic variations in the HPV type distribution in cervical cancer, using pooled analysis of data from two international studies. The data demonstrate that the public health impact of an HPV-16/18 vaccine could differ by geographic site.
41. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004; 328:57-63. An excellent review of HPV infection in HIV-infected men and women, including a discussion of both oral and anogenital HPV-related disease.
42. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 (Suppl 1):S97-S106. The author explains how mathematical modeling and the concept of herd immunity can be used to help inform which groups should be targeted for HPV and herpes simplex virus vaccines in order to maximize the public health impact of vaccination.
43. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615. The authors used mathematical modeling to project cancer incidence and mortality, life expectancy and cost-effectiveness associated with different cancer prevention policies, including HPV vaccination, cytologic screening (initiated at 18, 21, 25, 30 or 35 years), and combined vaccination and screening strategies. The authors suggest that a program of vaccination that permits a later age of screening initiation and a less frequent screening interval is likely to be a cost-effective use of Healthcare resources.
44. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000; 27:49-52.
45. Kahn JA, Bernstein DI. Human papillomavirus vaccines. Pediatr Infect Dis J 2003; 22:443-445.
46. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004; 58:1405-1413. The authors used in-depth individual interviews to explore parental attitudes about STI vaccination, including benefits and barriers to vaccination.
47. Zimet GD, Mays RM, Sturm LA, et al. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med 2005; 159:132-137. In this study, the authors examine parental willingness to allow STI vaccination for their adolescent children. The study focuses on the impact of mode of transmission (STI or non-STI), severity of infection, vaccine efficacy and availability of behavioral methods for prevention on parental willingness to agree to vaccination.
48. Mays RM, Zimet GD. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 2004; 31:428-432. In this study, the investigators explored attitudes of nurse practitioners regarding STI vaccination. The authors focus on the impact of the following factors on recommendation to vaccinate: STI type, patient age, patient gender and endorsement by the American Academy of Pediatrics.
49. Riedesel JM, Rosenthal SL, Zimet GD, et al. Family physicians' attitudes about HPV vaccines. J Pediatr Adolesc Gynecol (in press).
50. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccines: the role of provider characteristics, knowledge, and attitudes. J Adolesc Health (in press).
51. Raley JC, Followwill KA, Zimet GD, Ault KA. Gynecologists' attitudes regarding human papillomavirus vaccination: a survey of fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol 2004; 12:127-133.